# Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

> **NCT04003168** · PHASE1 · UNKNOWN · sponsor: **Hrain Biotechnology Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Human BCMA targeted T Cells Injection

## Key facts

- **NCT ID:** NCT04003168
- **Lead sponsor:** Hrain Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-01
- **Primary completion:** 2022-07
- **Final completion:** 2024-07
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2021-03-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003168, "Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04003168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*